Does the media favor COCH or VANI?

In the previous week, Envoy Medical had 1 more articles in the media than Vivani Medical. MarketBeat recorded 3 mentions for Envoy Medical and 2 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.25 beat Envoy Medical's score of 0.57 indicating that Vivani Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envoy Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VANI or SPRY?

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Vivani Medical's average media sentiment score of 1.25 beat ARS Pharmaceuticals' score of 0.91 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, AVIR or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is AVIR or VANI more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Vivani Medical N/A -191.05% -70.91%

Does the media favor AVIR or VANI?

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.46 beat Vivani Medical's score of 1.25 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VANI or CGC?

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 217.80%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media refer more to VANI or CGC?

In the previous week, Canopy Growth had 6 more articles in the media than Vivani Medical. MarketBeat recorded 8 mentions for Canopy Growth and 2 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.25 beat Canopy Growth's score of 0.98 indicating that Vivani Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivani Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Vivani Medical (VANI) Competitors

$1.18 -0.01 (-0.42%)

As of 02:30 PM Eastern

Compare

VANI vs. COCH, SPRY, AVIR, CGC, and FENC

Should you buy Vivani Medical stock or one of its competitors? Vivani Medical's main competitors and comparable companies include Envoy Medical (COCH), ARS Pharmaceuticals (SPRY), Atea Pharmaceuticals (AVIR), Canopy Growth (CGC), and Adherex Technologies (FENC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Vivani Medical compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Envoy Medical has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Envoy Medical presently has a consensus target price of $2.17, indicating a potential upside of 228.58%. Vivani Medical has a consensus target price of $3.75, indicating a potential upside of 217.80%. Given Envoy Medical's higher possible upside, equities research analysts clearly believe Envoy Medical is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Vivani Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-11,304.83%	N/A	-144.13%
Vivani Medical	N/A	-191.05%	-70.91%

8.6% of Envoy Medical shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 7.2% of Envoy Medical shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Envoy Medical had 1 more articles in the media than Vivani Medical. MarketBeat recorded 3 mentions for Envoy Medical and 2 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.25 beat Envoy Medical's score of 0.57 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envoy Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Envoy Medical has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	212.08	-$23.76M	-$0.76	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

Envoy Medical and Vivani Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does Vivani Medical compare to ARS Pharmaceuticals?

Vivani Medical (NASDAQ:VANI) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Vivani Medical has higher earnings, but lower revenue than ARS Pharmaceuticals. Vivani Medical is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
ARS Pharmaceuticals	$84.28M	4.78	-$171.30M	-$2.18	N/A

Vivani Medical has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Vivani Medical's return on equity of -191.05% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Vivani Medical has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Vivani Medical presently has a consensus price target of $3.75, indicating a potential upside of 217.80%. ARS Pharmaceuticals has a consensus price target of $25.00, indicating a potential upside of 517.28%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Vivani Medical and Vivani Medical both had 2 articles in the media. Vivani Medical's average media sentiment score of 1.25 beat ARS Pharmaceuticals' score of 0.91 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vivani Medical and ARS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Atea Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 40.56%. Vivani Medical has a consensus target price of $3.75, suggesting a potential upside of 217.80%. Given Vivani Medical's higher possible upside, analysts plainly believe Vivani Medical is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Atea Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market.

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Vivani Medical	N/A	-191.05%	-70.91%

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 53.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.46 beat Vivani Medical's score of 1.25 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Summary

Atea Pharmaceuticals beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

How does Vivani Medical compare to Canopy Growth?

Vivani Medical (NASDAQ:VANI) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Vivani Medical has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Vivani Medical has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
Canopy Growth	-65.33%	-21.91%	-14.34%

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 217.80%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Canopy Growth had 6 more articles in the media than Vivani Medical. MarketBeat recorded 8 mentions for Canopy Growth and 2 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 1.25 beat Canopy Growth's score of 0.98 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivani Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Canopy Growth	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivani Medical has higher earnings, but lower revenue than Canopy Growth. Vivani Medical is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
Canopy Growth	$251.01M	1.36	-$190.29M	-$0.45	N/A

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 0.4% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vivani Medical beats Canopy Growth on 9 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Adherex Technologies has higher revenue and earnings than Vivani Medical. Adherex Technologies is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.01	-$9.74M	-$0.13	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 53.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vivani Medical has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Vivani Medical	N/A	-191.05%	-70.91%

In the previous week, Vivani Medical had 1 more articles in the media than Adherex Technologies. MarketBeat recorded 2 mentions for Vivani Medical and 1 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 1.82 beat Vivani Medical's score of 1.25 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Very Positive
Vivani Medical	Positive

Adherex Technologies has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

Adherex Technologies currently has a consensus price target of $17.00, indicating a potential upside of 66.99%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 217.80%. Given Vivani Medical's higher possible upside, analysts clearly believe Vivani Medical is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Adherex Technologies beats Vivani Medical on 9 of the 14 factors compared between the two stocks.

Get Vivani Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VANI vs. The Competition

Export

Metric	Vivani Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$105.99M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-3.36	807.81	275.40	25.37
Price / Sales	N/A	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	5.88	9.21	10.55	5.95
Net Income	-$26.61M	$2.84B	$3.50B	$380.75M
7 Day Performance	-7.48%	-4.00%	-3.92%	-3.96%
1 Month Performance	-6.75%	-8.07%	-8.30%	-6.81%
1 Year Performance	-10.98%	-5.86%	2.35%	-4.58%

Vivani Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VANI Vivani Medical	2.9951 of 5 stars	$1.18 -0.4%	$3.75 +219.1%	-12.9%	$105.99M	N/A	N/A	36
COCH Envoy Medical	2.7311 of 5 stars	$0.66 +0.6%	$2.17 +229.5%	-26.6%	$50.44M	$207K	N/A	47	Analyst Forecast
SPRY ARS Pharmaceuticals	2.476 of 5 stars	$4.56 +4.6%	$25.00 +448.2%	-62.9%	$433.59M	$84.28M	N/A	200
AVIR Atea Pharmaceuticals	2.3375 of 5 stars	$5.16 +3.0%	$7.00 +35.7%	+60.1%	$401.83M	N/A	N/A	55
CGC Canopy Growth	1.194 of 5 stars	$0.85 -3.4%	N/A	-44.3%	$393.81M	$251.01M	N/A	1,128

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VANI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivani Medical (VANI) Competitors

VANI vs. COCH, SPRY, AVIR, CGC, and FENC

How does Vivani Medical compare to Envoy Medical?

Summary

How does Vivani Medical compare to ARS Pharmaceuticals?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Summary

How does Vivani Medical compare to Canopy Growth?

Summary

How does Vivani Medical compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivani Medical (VANI) Competitors

VANI vs. COCH, SPRY, AVIR, CGC, and FENC

How does Vivani Medical compare to Envoy Medical?

Which has more risk and volatility, COCH or VANI?

Do analysts rate COCH or VANI?

Is COCH or VANI more profitable?

Do insiders and institutionals believe in COCH or VANI?

Does the media favor COCH or VANI?

Which has preferable valuation and earnings, COCH or VANI?

Summary

How does Vivani Medical compare to ARS Pharmaceuticals?

Which has better valuation and earnings, VANI or SPRY?

Is VANI or SPRY more profitable?

Which has more volatility & risk, VANI or SPRY?

Do analysts prefer VANI or SPRY?

Does the media refer more to VANI or SPRY?

Do institutionals & insiders have more ownership in VANI or SPRY?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Do analysts prefer AVIR or VANI?

Which has more risk and volatility, AVIR or VANI?

Is AVIR or VANI more profitable?

Do insiders & institutionals have more ownership in AVIR or VANI?

Does the media favor AVIR or VANI?

Which has stronger valuation & earnings, AVIR or VANI?

Summary

How does Vivani Medical compare to Canopy Growth?

Which has more volatility and risk, VANI or CGC?

Is VANI or CGC more profitable?

Do analysts prefer VANI or CGC?

Does the media refer more to VANI or CGC?

Which has preferable valuation and earnings, VANI or CGC?

Do insiders and institutionals hold more shares of VANI or CGC?

Summary

How does Vivani Medical compare to Adherex Technologies?

Which has higher valuation & earnings, FENC or VANI?

Do institutionals & insiders believe in FENC or VANI?

Is FENC or VANI more profitable?

Does the media favor FENC or VANI?

Which has more risk & volatility, FENC or VANI?

Do analysts prefer FENC or VANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools